XOMA logo

XOMA ROYALTY CORPORATION

XOMANASDAQ
🏆 #2632 by market capUS Equity
$40.17▲ $0.00 (+0.00%)
🌅 Pre-market$39.35▼ 2.04%Regular close · extended-hours price shown
🔔
Track XOMA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.0%
7d—
14d—
30d—
ytd▲ 50.5%
1y▲ 20.9%
🏦Market Cap
$710M
Small Cap
📈Revenue Growth (YoY)
13.2%
Healthy
📊Gross Margin
100.0%
High
💵FCF Margin
25.9%
Strong
⚖️P/S Ratio
14.6x
Expensive
Otter Score
48
Weak

Trading Snapshot

Day Range
$39.87 – $43.53
52-Week Range
$22.29 – $45.22
Volume (shares)
0
Avg Volume (shares)
—
Shares Outstanding
17.7M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$52M
Last Q Revenue
$12M
P/E Ratio
21.0
P/S Ratio
14.6x
EPS (TTM)
$2.00
Dividend Yield
0.78%
Dilution (1yr)
+52.7%
XOMA logo

XOMA ROYALTY CORPORATION

XOMA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$52M▲ +83.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
94.3%▼ −5.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$11M▼ −128.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$3M▼ −120.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
18.1M▲ +52.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$49M▼ −$31M YoY
StockOtter · stockotter.space

About XOMA ROYALTY CORPORATION

XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main office in Emeryville, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
48/100

Analyst Ratings

ⓘ
Consensus
Buy
9 analysts
Strong Buy2
Buy4
Hold3
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

MarketBeat·Aug 26

Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital

Ligand Pharmaceuticals NASDAQ: LGND outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage asset base and plann

Defense World·Aug 13

Dimensional Fund Advisors LP Boosts Stock Holdings in XOMA Royalty Corporation $XOMA

Dimensional Fund Advisors LP grew its holdings in XOMA Royalty Corporation (NASDAQ: XOMA) by 207.7% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Co